Kategorie: Case Studies
-
How Tharimmune’s TH104 Navigated the FDA’s 505(b)(2) Pathway
From Simulation to Market: How Tharimmune’s TH104 Navigated the FDA’s 505(b)(2) Pathway to Address a National Security Threat The synthetic opioid crisis has evolved far beyond a public health emergency. When a substance fifty times more potent than heroin can be synthesized in a garage and weaponized as an aerosol, the line between pharmaceutical and…